Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease

被引：0
|
作者：
Robert Deicher
Walter H. Hörl
机构：
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] Universitätsklinik für Innere Medizin III,Klinische Abteilung für Nephrologie und Dialyse
来源：
Drugs | 2004年 / 64卷
关键词：
Chronic Kidney Disease; Subcutaneous Administration; Peritoneal Dialysis Patient; Sialic Acid Residue; Erythropoiesis Stimulate Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endogenous erythropoietin (EPO) consists of a central polypeptide core covered by post-translationally linked carbohydrates. Three of the four currently available erythropoiesis stimulating agents (ESA) — epoetin-α, epoetin-β and epoetin-ω — are composed of an identical amino acid sequence, but glycosylation varies as a result of type- and host cell-specific differences in the production process.
引用
收藏
页码：499 / 509
页数：10
相关论文
共 50 条
  • [21] Modulation of Platelet Activation in Chronic Kidney Disease Patients on Erythropoiesis-Stimulating Agents
    Farag, Youssef M. K.
    Keithy-Reddy, Sai Ram
    Mittal, Bharati V.
    Bansal, Vinod
    Fareed, Jaweed
    Singh, Ajay K.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2012, 18 (05) : 453 - 461
  • [22] Frequency of Administration of Erythropoiesis-Stimulating Agents for the Anaemia of End-Stage Kidney Disease in Dialysis
    Webster, Angela
    NEPHROLOGY, 2015, 20 (09) : 663 - 665
  • [23] Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease
    Kuwahara, Michio
    Mandai, Shintaro
    Kasagi, Yuri
    Kusaka, Keita
    Tanaka, Tomomi
    Shikuma, Satomi
    Akita, Wataru
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2015, 19 (04) : 598 - 605
  • [24] Responsiveness to Erythropoiesis-Stimulating Agents in Chronic Kidney Disease: Does Geography Matter?
    Luca De Nicola
    Francesco Locatelli
    Giuseppe Conte
    Roberto Minutolo
    Drugs, 2014, 74 : 159 - 168
  • [25] Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease
    Michio Kuwahara
    Shintaro Mandai
    Yuri Kasagi
    Keita Kusaka
    Tomomi Tanaka
    Satomi Shikuma
    Wataru Akita
    Clinical and Experimental Nephrology, 2015, 19 : 598 - 605
  • [26] OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
    Hoerl, W. H.
    Macdougall, I. C.
    Rossert, J.
    Schaefer, R. M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : III2 - III6
  • [27] Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review
    Bruce, Gordon
    Schulga, Peter
    Reynolds, Ben C.
    CLINICAL KIDNEY JOURNAL, 2022, 15 (08) : 1483 - 1505
  • [28] Responsiveness to Erythropoiesis-Stimulating Agents in Chronic Kidney Disease: Does Geography Matter?
    De Nicola, Luca
    Locatelli, Francesco
    Conte, Giuseppe
    Minutolo, Roberto
    DRUGS, 2014, 74 (02) : 159 - 168
  • [29] Re: Testosterone Deficiency is a Cause of Anaemia and Reduced Responsiveness to Erythropoiesis-Stimulating Agents in Men With Chronic Kidney Disease Editorial Comment
    Seftel, Allen D.
    JOURNAL OF UROLOGY, 2012, 187 (01): : 236 - 236
  • [30] Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients
    Hahn, Deirdre
    Cody, June D.
    Hodson, Elisabeth M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (05):
12345